178 related articles for article (PubMed ID: 9586680)
1. Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis.
al-Sewairy W; al-Mazyed A; al-Dalaan ; al-Balaa S; Bahabri S
Clin Rheumatol; 1998; 17(1):52-7. PubMed ID: 9586680
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study.
Truckenbrodt H; Häfner R
Arthritis Rheum; 1986 Jun; 29(6):801-7. PubMed ID: 3718568
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of methotrexate therapy for juvenile rheumatoid arthritis.
Lin YT; Tsai MJ; Wang LH; Huang MT; Yang YH; Chiang BL
J Formos Med Assoc; 2000 Aug; 99(8):623-9. PubMed ID: 10969505
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate in the treatment of children with chronic arthritis--long-term observations of efficacy and safety.
Huang JL
Br J Clin Pract; 1996 Sep; 50(6):311-4. PubMed ID: 8983319
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
Kostik MM; Gaidar EV; Hynnes AY; Dubko MF; Masalova VV; Snegireva LS; Chikova IA; Isupova EA; Nikitina TN; Serogodskaya ED; Kalashnikova OV; Ravelli A; Chasnyk VG
Clin Exp Rheumatol; 2016; 34(4):714-8. PubMed ID: 27385618
[TBL] [Abstract][Full Text] [Related]
6. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
7. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
[TBL] [Abstract][Full Text] [Related]
8. [Methotrexate treatment in refractory juvenile rheumatoid arthritis].
Brik R
Harefuah; 1998 Dec; 135(11):509-11, 567. PubMed ID: 10911466
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.
Gottlieb BS; Keenan GF; Lu T; Ilowite NT
Pediatrics; 1997 Dec; 100(6):994-7. PubMed ID: 9374571
[TBL] [Abstract][Full Text] [Related]
10. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis.
Wallace CA; Sherry DD
J Rheumatol; 1992 Oct; 19(10):1604-7. PubMed ID: 1464876
[TBL] [Abstract][Full Text] [Related]
11. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis.
Falcini F; Taccetti G; Ermini M; Trapani S; Calzolari A; Franchi A; Cerinic MM
Arthritis Rheum; 1997 Jan; 40(1):175-8. PubMed ID: 9008613
[TBL] [Abstract][Full Text] [Related]
13. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
Fráňová J; Fingerhutová Š; Kobrová K; Srp R; Němcová D; Hoza J; Uher M; Saifridová M; Linková L; Doležalová P
Pediatr Rheumatol Online J; 2016 Jun; 14(1):36. PubMed ID: 27301536
[TBL] [Abstract][Full Text] [Related]
15. Etanercept in systemic juvenile idiopathic arthritis.
Russo RA; Katsicas MM; Zelazko M
Clin Exp Rheumatol; 2002; 20(5):723-6. PubMed ID: 12412209
[TBL] [Abstract][Full Text] [Related]
16. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
Ravelli A; Viola S; Migliavacca D; Ruperto N; Pistorio A; Martini A
J Pediatr; 1999 Sep; 135(3):316-20. PubMed ID: 10484796
[TBL] [Abstract][Full Text] [Related]
17. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis.
Graham LD; Myones BL; Rivas-Chacon RF; Pachman LM
J Pediatr; 1992 Mar; 120(3):468-73. PubMed ID: 1538301
[TBL] [Abstract][Full Text] [Related]
18. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.
van Dijkhuizen EH; Wulffraat NM
Pediatr Rheumatol Online J; 2014; 12():51. PubMed ID: 25525416
[TBL] [Abstract][Full Text] [Related]
19. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis.
Shetty AK; Zganjar BE; Ellis GS; Ludwig IH; Gedalia A
J Pediatr Ophthalmol Strabismus; 1999; 36(3):125-8. PubMed ID: 10358815
[TBL] [Abstract][Full Text] [Related]
20. Erythrocyte-methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis.
Kristensen K; Nielsen S; Karup Pedersen F; Zak M
Scand J Rheumatol; 2000; 29(3):187-9. PubMed ID: 10898073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
